Dosimetry and optimal scan time of [18F]SiTATE-PET/CT in patients with neuroendocrine tumours

• DOI: 10.1007/s00259-021-05351-x
• Publication Date: 2021-04-29T21:39:12Z
• Authors: Leonie Beyer; Astrid Gosewisch; Simon Lindner; Friederike Völter; Lena M. Mittlmeier; Reinhold Tiling; Matthias Brendel; Clemens C. Cyran; Marcus Unterrainer; Johannes Rübenthaler; Christoph J. Auer...; Christine Spitzweg; Guido Böning; F. J. Gildehaus; Klaus Jurkschat; Carmen Wängler; Björn Wängler; Ralf Schirrmacher; Vera Wenter; Andrei Todica; Peter Bartenstein; Harun Ilhan
• Keywords: Biodistribution; Neuroendocrine tumour; PET-CT; Positron emission

Radiolabelled somatostatin analogues targeting receptors (SSR) are well established for combined positron emission tomography/computer tomography (PET/CT) imaging of neuroendocrine tumours (NET). [18F]SiTATE has recently been introduced showing high image quality, promising clinical performance and improved logistics compared to the reference standard 68Ga-DOTA-TOC. Here we present first dosimetry optimal scan time analysis.Eight NET patients received a [18F]SiTATE-PET/CT (250 ± 66 MBq) with repeated scans (10, 30, 60, 120, 180 min after injection). Biodistribution in normal organs SSR-positive tumour uptake were assessed. Dosimetry estimates risk determined using linear-monoexponential model, by applying 18F S-values target masses ICRP89 adult male or female (OLINDA 2.0). Tumour-to-background ratios quantitatively visually between different times.After 1 h, showed similar tracer only negligible changes until 3 h post-injection. In contrast, increased progressively almost all types metastases, thus increasing tumour-to-background over time. resulted total effective dose 0.015 0.004 mSv/MBq. Visual evaluation revealed no clinically relevant discrepancies later times, but quality was rated highest 60 120 images.[18F]SiTATE-PET/CT shows overall from injection an comparable 68Ga-labelled alternatives. For use [18F]SiTATE, best compromise contrast is reached at min, followed injection.